New York, October 31, 2024 - PRISM MarketView - Anavex Life Sciences (Nasdaq: AVXL) presented data at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference from their Phase 2b/3 trial of blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease (AD) patients. The trial results indicate that the once-daily oral drug met pre-specified efficacy criteria, showing slowed clinical decline and a favorable safety profile without neuroimaging-related side effects. AVXL shares are currently trading up 9%.
The study demonstrated that blarcamesine slowed disease progression by 36.3% in the general trial population, with a stronger effect (49.8% slower progression) in patients with the common SIGMAR1 gene variant, suggesting a possible genetic basis for treatment response. Blarcamesine’s mechanism of action, involving SIGMAR1 activation, supports autophagy—a process that helps maintain cellular balance by clearing protein aggregates linked to neurodegeneration. This unique action could offer a complementary or alternative approach to existing Alzheimer’s treatments.
“Alzheimer’s disease is such a devastating disease that affects tens of millions worldwide. We believe, the clinically meaningful study results provide the potential for patients and their families to have a better and longer quality of life. We believe the scalable and convenient features of blarcamesine could reduce crucial barriers within the currently complex healthcare ecosystem for Alzheimer’s disease and provide broader access to a diverse population with early Alzheimer’s disease.”
Christopher U. Missling, PhD, CEO of Anavex
The study also reported that blarcamesine’s once-daily oral formulation could provide an accessible option for AD management, potentially easing healthcare delivery challenges and broadening patient access. Anavex plans to submit the drug for regulatory review in Europe (EMA) by the end of 2024.
Earlier this month, the Company reported encouraging preliminary biomarker results from its ongoing phase 2 study of ANAVEX®3-71 for the treatment of schizophrenia.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities